Michele Wozniak - Astellas Pharma Inc

基本信息

Career Trajectory

Bio

No content for now

Research Interests

Papers共 7 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

HSD3B1 Genotype and Outcomes in Metastatic Hormone-Sensitive Prostate Cancer with Androgen Deprivation Therapy and Enzalutamide: ARCHES

Nima Sharifi, Arun A. Azad,Mona Patel,Jason W. D. Hearn,Michele Wozniak,Fabian Zohren,Jennifer Sugg,Gabriel P. Haas,Arnulf Stenzl,Andrew J. Armstrong

CELL REPORTS MEDICINEno. 8 (2024)

Cited0Views0WOSBibtex

Enfortumab Vedotin (EV) in Previously Treated Gastric/esophageal Cancers Cohorts of EV-202

Kei Muro,Keisho Chin, Steven Brad Maron, Fadi S. Braiteh,Seiichiro Mitani, Hiroki Hara,Yasutoshi Kuboki,Mary F. Mulcahy, Joaquina Celebre Baranda, Faithlore Patrice Gardner, Ning Jin,Satoshi Hamauchi, Jason Kaplan, Seema Rao Gorla, Shubin Liu,Michele Wozniak, Changting Meng,Shunsuke Kondo

JOURNAL OF CLINICAL ONCOLOGYno. 16 (2024)

Cited0Views0Bibtex

Enfortumab Vedotin (EV) in Triple-Negative Breast Cancer (TNBC) and HR+/HER2- Breast Cancer (BC) Cohorts of EV-202

Antonio Giordano, Ali,Justine Yang Bruce,Hope S. Rugo,Jennifer Robinson Diamond,Yelena Novik,Joaquina Celebre Baranda,Kei Muro,Makiko Ono,Rita Nanda, Jason Kaplan, Seema Rao Gorla, Shubin Liu,Michele Wozniak, Anthony Lee,Tiffany A. Traina

Journal of Clinical Oncologyno. 16_suppl (2024): 1005-1005

Cited0Views0Bibtex

Enfortumab Vedotin (EV) in Non-Squamous and Squamous Non–small Cell Lung Cancer (NSCLC) Cohorts of EV-202

Kei Muro,Trevor Feinstein,Joaquina Celebre Baranda,Ioana Bonta, Satoru Kitazono, Todd A. Gersten, Leena Gandhi,Toshihiro Kudo, Jason Kaplan, Seema Rao Gorla, Shubin Liu,Michele Wozniak, Anthony Lee,Tejas Patil

JOURNAL OF CLINICAL ONCOLOGYno. 16 (2024)

Cited0Views0Bibtex

Phase II Trial of Enfortumab Vedotin in Patients with Previously Treated Advanced Head and Neck Cancer

Paul L Swiecicki,Emrullah Yilmaz, Ari Joseph Rosenberg, Takao Fujisawa, Justine Yang Bruce, Changting Meng,Michele Wozniak, Yongyun Zhao, Michael Mihm, Jason Kaplan, Seema Gorla, Jessica L Geiger

Journal of clinical oncology official journal of the American Society of Clinical Oncologypp.JCO2400646-JCO2400646, (2024)

Cited0Views0WOSBibtex

Prevalence of DNA damage repair (DDR) alterations in patients with metastatic hormone-sensitive prostate cancer (mHSPC) receiving enzalutamide (ENZA) or placebo (PBO) plus androgen deprivation therapy (ADT): ARCHES post hoc analysis

Arun Azad,Taro Iguchi,Boris Alekseev,Neal D. Shore,Jennifer Sugg,Gabriel P. Haas,Michele Wozniak,Thomas O'Brien,Douglas Laird,Arnulf Stenzl,Andrew J. Armstrong

Journal of Clinical Oncology（2022）

Cited0Views0Bibtex

The Association of Germline HSD3B1 Genotype with Outcomes in Metastatic Hormone-Sensitive Prostate Cancer (mhspc) Treated with Androgen Deprivation Therapy (ADT) with or Without Enzalutamide (ENZA) [ARCHES]

Nima Sharifi,Arun Azad,Mona Patel,Jason W. D. Hearn,Michele Wozniak,Fabian Zohren,Jennifer Sugg,Gabriel P. Haas,Arnulf Stenzl,Andrew J. Armstrong

Journal of clinical oncology（2022）

Cited0Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn